Introduction
The angiotensin AT2 receptor (AT2R) has been increasingly recognized as an integrative part of the protective arm of the renin-angiotensin system (RAS). Although it shares with theAT1R 1. Cardiac Aspects
AT2 receptor in cardiac function
The AT2 receptor (ATR2)-mediated actions in the cardiovascular system are very complex. Nevertheless, the bulk of investigations performed in the last decade indicate that activation of the AT2R leads to a protective response in the heart (Fig. 1) .
In the heart, AT2Rs are present in fibroblasts, myocytes and endothelial cells and are regulated in different ways, depending on the time after injury (for review see [1] ). For instance, one week after myocardial infarction (MI), expression of the AT2Rs in the rat heart were enhanced [2, 3] and co-localised with the inflammatory T-cells [4] and progenitor cells [5] in the peri-infarct zone. However, in the intermediate phase post MI [6] and in left ventricular dysfunction the AT2Rs were down-regulated [7] . Initially, studies performed in genetically altered (AT2R KO) mice have demonstrated protective effects of AT2R stimulation in the early phase post MI [8] [9] [10] [11] . Our group investigated the effects of direct AT2R stimulation with compound 21 (C21) on post-MI myocardial function in the early [12] and late phase post MI [13] in normotensive rats. AT2R activation significantly reduced scar formation and prevented left ventricular dilatation and dysfunction as evidenced by an improvement in cardiac parameters (LVIDd, LVIDs, EF, FS, dP/dt max, dP/dt min, E/A-ratio), contractility index and a reduction in the end-diastolic pressure. Importantly, these effects of C21 were AT2R-specific since they were inhibited by co-treatment with the AT2R antagonist, PD 123319 [12] . Moreover, for a number of parameters, C21 was even more effective than the AT1 receptor antagonist, candesartan, which was used as a reference drug [12] . Altogether, C21 improved systolic and diastolic cardiac function both 7 days and 6 weeks after MI.
A study by Qi et al. [14] showed that moderate cardiac-selective overexpression of the AT2R via application of rAAV9-CBA-AT2R to the peri-infarcted myocardial area improved fractional shortening and decreased left ventricular end-diastolic pressure. Also in genetically altered mice, AT2R overexpression had protective effects on postinfarction left ventricular remodeling and cardiac performance in the late phase post MI [10, 15] . On the other hand, the AT2R may also impact the overall cardiac function specifically via the intrinsic cardiac nervous system. Hardwick and colleagues studied the role of AT1-and AT2 receptors in the autonomic remodeling process that follows myocardial infarction in the guinea pig intrinsic plexus [16] . Stimulation of the AT2R with CGP42112A prevented the upregulation in adrenergic sensitivity of the intrinsic cardiac neurons after MI.
Conversely, two studies in mice reported no impact of the AT2R on post-MI cardiac performance [17, 18] . AT2R deficiency had no significant influence on left ventricular function or on cardiac remodeling in mice after induction of MI, although AT2R-knockout mice had less cardiac collagen content under basal conditions [17] . In a mouse occlusion-reperfusion model, Jehle and colleagues [18] also did not find any improvement of left ventricular remodelling after direct AT2R stimulation with C21. This fact could be explained by a low dose of C21 used for the treatment.
However, taken together, there is accumulating evidence to suggest that the AT2R stimulation post MI is cardioprotective. Infarct size reduction and improvement of cardiac performance after acute MI could be explained by beneficial cellular mechanisms of the AT2R activation, such as anti-inflammation, anti-apoptosis, activation of bradykinin/NO/cGMP system and tissue regeneration processes in the early phase after MI as well as anti-fibrosis and prevention of extracellular matrix degradation in the late phase post MI. All these possible protective mechanisms are depicted in Fig. 1 and will be discussed below.
Anti-inflammatory mechanisms of AT2R in the heart
One week post MI, AT2R stimulation with C21 significantly decreased the inflammatory status as shown by myeloperoxidase (MPO) and cytokines MCP-1, IL-1ß, IL-2, IL-6 in plasma and the peri-infarct zone [12] . Furthermore, Curato and colleagues reported about a cardiac CD8 + AT2R + T cell population, which exhibited down-regulated expression of proinflammatory cytokines IL-2 and INF-␥ [4] . In this study, AT2R activation by C21 one week post MI stimulated an increase in cardiac CD8 + AT2R + T cells. Consequently, intramyocardial transplantation of these cells reduced infarct size in recipient rats post MI [4] . The protective role of the AT2R was also attributed to enhanced production of IL-10 in the heart. Similarly, an AT2R-mediated anti-inflammatory response via enhanced IL-10 has been recently demonstrated in THP-1 macrophages [19] . In this study, C21 attenuated TNF-␣ and IL-6 production in response to activation of TLR4 by LPS. This effect was explained by increased IL-10 production via a sustained, selective increase in ERK1/2 phosphorylation [19] .
Other anti-inflammatory mechanisms of direct AT2R stimulation by C21 have been attributed to inhibition of JAK/STAT signaling, inhibition of NF-kB and inhibition of COX2 synthesis (for review see [20] ). Moreover, recent findings by Zhu and colleagues suggest that stimulation of AT2R reduces TNF-␣-stimulated ICAM-1 expression, partly through ACE2-mediated inhibition of NF-B signaling [21] ( Fig. 1 ).
AT2R -mediated activation of bradykinin/NO/cGMP system in the heart
Nitric oxide (NO)-stimulated soluble guanylyl cyclase generates cGMP, which exerts tissue protective effects (for review see [22] [23] [24] ). An AT2R -mediated activation of the bradykinin/NO/cGMP system has been previously demonstrated in endothelial cells [25] , the aorta [26] and the heart [27] . Using a model of post-MI heart failure in rats, Liu and colleagues suggested that the cardioprotective role of kinins is partly due to the activation of the AT2 receptor [27] . In cardiomyocytes, AT2R stimulation activated kininogenase and, consequently, the bradykinin/B2-receptor/NO axis [28] . Jalowy and colleagues reported that indirect AT2R stimulation reduced infarct size in pigs, and this effect was antagonised by the B2R blocker icatibant [29] . In addition, in human tissue, AT2R-stimulated bradykinin production and activation of NO/cGMP pathway induced vasodilatation of human coronary microvessels in a paracrine manner [30] . NO-dependent mechanisms were also shown to be important for AT2R-mediated anti-fibrosis and anti-remodeling after MI [27, [31] [32] [33] and have been reviewed recently in detail [34] .
The mechanism of the interaction between the AT2R and NO/cGMP system is considered to be directly or indirectly B2R-dependent (for review see [20, 35] ). Evidence for a functional heterodimerization of the AT2R and B2R have also been reported [36] . Interestingly, NO may have a newly discovered positive feedback mechanism via upregulation of the AT2R, at least in vascular endothelial cells [37] . Moreover, in isolated mitochondria, AT2R stimulation increased NO production and suppressed respiratory oxygen consumption pointing to the role of intracellular AT2R [38] .
AT2R -mediated anti-apoptosis in the heart
It is widely accepted that AT2 receptor activation can induce programmed cell death under appropriate conditions (for review see [20, 39] ). Nevertheless, our group provided evidence that in the early phase post MI the AT2R mediates anti-apoptosis [12] . In a rat model of MI, treatment with C21 ameliorated MI-related expression of apoptotic markers Fas-ligand and caspase-3. Importantly, Fig. 1 . Mechanisms involving AT2R-mediated cardiac protection. The AT2 receptor activation prevents the development of pathological processes such as inflammation, activation of the sympathetic nervous system, apoptotic cell death, autophagy, cardiac fibrosis and arterial stiffness. Parallel, AT2 receptor stimulation activates defence mechanisms in the heart such as cardiac regeneration, vasodilation of coronary microvessels and compensatory hypertrophy of cardiac myocytes. AT2 receptor activation is also indirectly responsible for the up-regulation of the Mas receptor (MasR), ACE2 activity and Ang-(1-7) levels which may contribute to protective mechanisms also. Cardiac protection via the AT2 receptor stimulation results in decreased left ventricular remodelling and functional improvement of the heart that, in turn, may prevent nephropathies, kidney fibrosis and cardio-renal syndrome. BK: bradykinin; NO: nitric oxide; cGMP: cyclic guanosine monophosphate; eNOS: endothelial nitric oxide synthase; NF-kB: nuclear factor kB; TNF␣: tumor necosis factor this effect was AT2R-specific since it was blunted by the AT2R-antagonist, PD 123319. Furthermore, the rescue of p38 and p44/42 MAPK (mitogen activated protein kinase) by AT2R stimulation also contributed to an anti-apoptotic effect [12] .
Further investigations conducted by Altarche-Xifró and colleagues [5] showed that AT2R stimulation attenuated apoptosis indirectly by cardiac c-kit + AT2+ cell population. This antiapoptotic mechanism has been attributed to activation of Stat-3 and Akt signalling pathways [5] . Interestingly, AT2R stimulation also inhibited autophagy cell death mediated by the AT1R in cardiomyocytes [40] Altogether, AT2R activation prevents cells death in the heart and, therefore, may interrupt the pathomechanisms leading to infarct expansion, ventricular remodeling and heart failure ( Fig. 1) . Further studies are needed to clarify the controversies about AT2R related apoptosis/anti-apoptosis in other pathophysiological models.
AT2R in cardiac regeneration
The role of the AT2R in tissue regeneration processes has been previously widely investigated in the context of neuroregeneration (reviewed in [20] ). Along with these studies, recent research implicates AT2R in cardiac regeneration (Fig. 1) .
Altarche-Xifró and colleagues showed AT2R up-regulation in c-kit + stem cells in the peri-infarct zone of rats subjected to MI [5] . This c-kit + AT2+ cell population was characterized by up-regulation of transcription factors responsible for cardiogenic differentiation (Gata-4, Notch-2, Nkx-2.5) and genes required for self-renewal (Tbx-3, c-Myc, Akt) [5] . The preconditioning of bone marrow mononuclear cells with an AT2R agonist CGP42112A or indirectly with Ang II plus AT1R antagonist led to ERK activation and increased NO generation via eNOS [32] . Moreover, transplantation of preconditioned cells in the heart decreased infarct size and improved cardiac performance post MI [32] .
Recently, Skorska and colleagues defined a CD4 + AT2R + T cell population acting as a 'regulatory' T cell subset facilitating cardiac regeneration [41] . These cells expressed regulatory FoxP3, secreted interleukin-10 and improved heart function post-MI corresponding with reduced infarction size in a rat model of MI. Furthermore, intramyocardial application of MI-induced splenic CD4 + AT2R + T cells to rats with MI led to reduced infarct size and improved cardiac performance. In addition, AT2R expression on human peripheral blood CD4 + T cells was higher in healthy donors than in heart failure patients [41] .
All these results suggest that the AT2R stimulation via myocardial transplantation, pharmacological AT2R activation or a combination thereof are promising for regenerative therapy.
AT2R in extracellular matrix degradation and cardiac fibrosis
A number of studies have now provided evidence for an antifibrotic activity of AT2R stimulation in the heart and vessels (Fig. 1) . Our group demonstrated that treatment with C21 attenuated interstitial fibrosis and collagen accumulation in the remote myocardium 6 weeks post MI and, at the same time, reduced arterial stiffness [13] . Similarly, anti-fibrotic effects of AT2R stimulation with C21 has been shown in the aorta of L-NAME treated hypertensive rats [42] and in the vessels and the heart of hypertensive SHR [43] . Both, treatment with C21 [13] and AT2R overexpression [14] attenuated increased collagen I expression in the heart after MI.
Pathological fibrotic processes are characterized by collagen accumulation and extacellular matrix degradation due to dysregulation of the MMP/TIMP axis and transforming growth factor beta 1 (TGF-␤) signalling pathways. In our study, the anti-fibrotic effect of AT2R stimulation with C21 in the heart post MI was associated with a dramatic down-regulation of TGF-␤1 [13] . C21 also attenuated the TGF-␤1 mRNA increase in primary cardiac fibroblasts suggesting direct regulation through AT2R [13] . Furthermore, in the heart of L-NAME treated hypertensive rats C21 attenuated mRNA expression of TGF-␤1 coinciding with decreased BNP levels [44] . Recently, Xu J and colleagues examined the effects of cardiac overexpression of the AT2R gene on remodeling and dysfunction in mice post-MI [33] . Whether overexpression of AT2R is beneficial or detrimental to the heart was largely dependent on the expression levels of the receptor and related to TGFˇ1 [33] .
As mentioned above, fibrotic processes are closely connected with the extracellular matrix turnover processes, which in turn are regulated by matrix metalloproteinases (MMPs) and its natural inhibitors TIMPs. The degradation of matrix components by MMPs, especially by MMP2 and MMP9, may contribute to left ventricular wall thinning in the remote region after MI [45] . Moreover, TIMP1 deficiency plays a negative role in post MI heart remodelling by promoting left ventricular dilatation and increasing LVEDV [46] . Lauer and colleagues found that the proteolytic disbalance in the heart post MI in rat, followed by increased MMP9/TIMP1 ratio, was ameliorated by treatment with C21. Interestingly, in single cardiac fibroblasts, C21 primarily activated TIMP1 that in turn inhibited MMP9 [13] .
Thus, the above studies support the anti-fibrotic role of the AT2R in the heart and suggest a functional link between AT2R, TGF-␤1
and MMPs/TIMPs axis in remodeling processes. To firmly establish a causal relationship requires further investigations.
AT2R in left ventricular hypertrophy
Activation of the AT2R was proposed to counteract growth effects of the AT1R in response to Ang II [1] . Nevertheless, there is accumulating evidence to suggest that the contribution of the AT2R to cardiac hypertrophy is very complex (for review see [35, 47] ).
In early studies, antigrowth effects of the AT2R were found in several cell types, e.g. cultured coronary endothelial cells, neonatal cardiomyocytes and fibroblasts (for review see [48] ). Studies performed in genetically altered mice models also confirmed the antigrowth effects of the AT2R. For instance, in mice lacking the AT2R, post MI myocardial cross-sectional areas [28] and heart/body weight ratios were increased [15, 31] . Consistently, AT2R gene overexpression in SHRs decreased left ventricular wall thickness [49] , and intracardiac gene transfer attenuated hypertrophy in Ang II-infused rats [50] . Similarly, aortic banding in mice with overexpression of AT2R-TG resulted in decreased cardiomyocyte diameter [51] . In a hypertension-induced model of left ventricular hypertrophy (SHR-SP), AT2R stimulation with C21 led to anti-hypertrophic effects on the heart and reduced the expression of cardiac genes associated with cardiac hypertrophy [43] (Fig. 1) .However, some studies reported that the AT2R stimulation also promote growth.
Increased AT2R expression in rat neonatal cardiomyocytes resulted in Ang II -dependent cell growth [52] . In Ang II overload [53] and pressure overload [54] − induced cardiac hypertrophy models, AT2R contributed to progression of ventricular hypertrophy. Our group provided evidence that treatment with C21 reinforced hypertrophy of cardiac myocytes by increasing the cell diameters 6 weeks after MI [13] . Importantly, this fact coincided with significant functional improvement of the heart. Voros and colleagues observed a similar tendency in the mouse model of MI [55] . Thus, an induction of compensatory hypertrophy post MI may be considered as a positive mechanism, by which the AT2R contributes to cardiac protection (Fig. 1) .
The antigrowth effect of AT2R stimulation has been attributed to activation of protein tyrosine phosphatase SHP-1 and interaction with an AT2R binding protein ATBP (for review see [56] ). The growth effect may be explained by AT2R -mediated activation of PLZF (Promyelocytic Leukemia Zinc Finger Protein). Moreover, PLZF may prevent AT2R interaction with SHP-1 (for review see [57] ).
Summarising, until now, the contribution of the AT2R to cardiac hypertrophy is inconsistent. AT2R mediates the cardiac hypertrophic process depending on the pathophysiological conditions by regulating the expression of growth-promoting and growthinhibiting factors.
Renal Aspects

Renal AT2R expression
The AT2 receptor expression pattern may differ between studies, since it is species, age and methodology dependent. Similarly to the cardiovascular tissue, renal expression of the AT2R is high during fetal development and rapidly decreases after birth [58, 59] . In the fetal kidney, AT2R is mostly expressed in mesenchymal tissues [60] , which may suggest its involvement in kidney development. In the adult healthy kidney, AT2R expression in generally low and found predominantly in the adventitia of the arcuate and interlobular arteries and the renal capsule [61] . Glomerular expression of AT2R was reported by Ozono et al. [62] but undetectable by Miyata et al. [63] . In the adult kidney, several mechanisms, often related to tissue injury, may lead to AT2R re-expression. Ozono et al. demonstrated that sodium depletion up-regulates glomerular and tubular AT2R expression in adult rat [62] . Three days infusion of Ang II leads to an increased AT2R immunoreactivity in rat tubuloepithelial cells and glomeruli but restricted to glomeruli in mice [64] . This was accompanied by infiltration of immune cells suggesting involvement of inflammatory processes (via AT1R) in the AT2R up-regulation. However, elevated AT2R expression upon Ang II infusion was found in AT1R knock out animals [64] suggesting a positive feedback loop between AT2R stimulation and its expression (Fig. 2) . Later on, Reinemund et al. confirmed these findings using a promoter assay by showing that Ang II alone or in combination with an AT1R blocker leads to an up-regulation of the AT2R [65] . In pathological conditions involving acute renal tissue damage, the expression of AT2R seems to be massively increased (Fig. 2) . In animal models of folic acid nephropathy and protein overload proteinuria, up-regulation of AT2R was found in tubular cells [64] . In a unilateral ureteral obstruction (UUO) model in mice, the AT2R mRNA was elevated in obstructed kidneys compared with contralateral ones [66] . In contrast, animal models of chronic kidney disease rather show a down-regulation of the AT2R expression (Fig. 2) . In hemi-nephrectomized mice treated with uremic toxins (indoxyl sulfate or p-cresol sulfate) for four weeks, a decreased expression of AT2R was observed [67] . In diabetic hypertensive rats (streptozotocin-treated SHRs), a significant reduction in glomerular and tubulo-interstitial AT2R expression was observed in diabetic compared with control animals after 32 weeks of disease [68] . Interestingly, in acute renal hypertension rat models, 7 days 2-kidney 1-clip and 3 days 2-kidney 1-figureof-8-wrap reduced AT2R expression was observed in the ischemic kidney as compared to the contralateral kidney or healthy controls [69] .
Renal AT2R expression in human samples has been only rarely investigated and the studies provide inconsistent results. Mifune at al analysed renal expression of the AT2R in kidney biopsies obtained from minimal change disease (4 patients), IgA nephropathy (6 patients), membranous glomerulonephritis (8 patients) and control subjects (3 patients undergoing nephrectomy for renal tumors). No differences in AT2R expression between diseased and control samples in glomerular, vascular or tubulointerstitial areas were found [70] . In contrast, del Prete showed that the AT2R was expressed in glomerular tissues in 16 out of 20 patients with IgA nephropathy and almost absent in all 8 control patients [71] . Expression of the AT2R has been also studied in renal biopsies from diabetic nephropathy (DN) patients. In tissue samples obtained from 10 patients with DM an elevated expression of AT2R as compared to control tissue (n = 5; renal tumor patients) was found [72] . The inconsistence in AT2R expression in human biopsy samples might be related to a low number of subjects involved (statistical power), detection methods used (radiography > qPCR > immunostaining), sample preparation (whole biopsy tissue vs microdissection), disease stage, patient's age and many other factors and should therefore be interpreted with caution.
Renal AT2R function in health
The renin-angiotensin system, especially its AT1R, has been historically linked to blood-pressure regulation, fluid and electrolyte balance [1] . One of the key mechanisms involved in these processes is the so-called pressure natriuresis defined as a protective mechanism by which increased blood pressure (BP) mediates an increase in renal perfusion pressure and this leads to an increase sodium excretion down regulating BP to control levels [73] . While the impact (and underlying mechanisms) of the AT1R in pressure natriuresis has been well described, the role of AT2R is not fully understood. Based on indirect evidence it has been postulated that AT2R may promote natriuresis, clearly demonstrated first in 1999 by Siragy et al. (the Fig. 2) . In AT2R knock out mice, Ang II infusion results in sustained antinatriuresis compared to wild-type animals [74] . The postulated underlying mechanism involves the bradykinin/nitric oxide/cyclic GMP pathway [74] . Further study utilising direct renal interstitial microinfusion of pharmacological agents (thus without systemic effects) showed that local administration of the AT1R blocker, candesartan, promoted natriuresis that was abolished by concomitant administration of the AT2R blocker, PD123319, [75] , indicating involvement of AT2R in natriuresis. Subsequent studies implicated that Ang III (not Ang II) is the canonical AT2R ligand in the regulation of renal sodium excretion and that Ang II has to be converted to Ang III (by aminopeptidase A) to promote an AT2R-dependent natriuretic response [76, 77] . The AT2R-mediated natriuresis might be triggered not only by endogenous ligands, but also by selective pharmacological agonists. Using the AT2R agonist, C21, it has been shown that selective AT2R stimulation promotes natriuresis in uninephrectomized Sprague-Dawley rats [77] , anesthetized male and female Sprague-Dawley rats [78] and in obese Zucker rats [79] .
Utilising the above-mentioned mechanism (renal nitric oxide/cyclic GMP cascade) it has been also shown that the AT2R inhibits renin synthesis [80, 81] (Fig. 2). 
AT2R deficiency/overexpression in kidney diseases
In AT2R deficient animals, no gross developmental alterations have been observed [82] although differences in glomerular size and function have been reported [83] suggesting a role of the AT2R in nephrogenesis. The first evidence indicating a protective role of the AT2R in kidney disease came from studies utilizing AT2R-KO animals. In general there is a consensus that AT2R deletion accelerates disease progression as compared to the wild type (WT) animals (summarized by [84] ).
In unilateral ureteral obstruction (UUO) in mice, a model of semi-acute injury and fibrosis characterized by an activated RAS, enhanced interstitial fibrosis and elevated numbers of fibroblasts/myelofibroblasts were present in obstructed kidneys from AT2R-KO as compared to WT animals [85] . This was accompanied by diminished cell apoptosis indicating the importance of AT2R in tissue remodelling related to kidney disease.
The anti-fibrotic mechanisms mediated by AT2R were studied in UUO model with AT2R-KO and WT animals (Fig. 2) . As expected renal fibrosis (as assessed with collagen I and IV staining) was elevated in AT2R-KO animals [86] . Importantly, the authors provided experimental evidence that the anti-fibrotic actions of AT2R were mediated by heterodimers of AT2R and the relaxin receptor RXFP1. Binding of relaxin to AT2R/RXFP1 complexes disrupted the profibrotic actions of transforming growth factor-␤1 (TGF-␤1) via a nNOS-NO-cGMP-dependent pathway (Fig. 2) .
Using a well-characterized model of chronic renal injury, the 5/6 nephrectomy, the authors found a greater impairment of renal function (albuminuria, elevated plasma creatinine and urea-N), glomerular injury (infiltration of monocytes/macrophages), and mortality in AT2R-KO mice than in WT mice [87] . No differences in renin expression or systolic blood pressure between both animal groups were present but, surprisingly, elevated eNOS expressions in the kidneys of AT2R-KO were noticed. This was accompanied by elevated levels of plasma ADMA, an important endogenous inhibitor of nitric oxide synthases, which may explain the lack of eNOS-derived NO protection.
Another group, using the same disease model, the 5/6 nephrectomy, tested the impact of AT2R overexpression (AT2R-Tg) on disease progression. Albuminuria, glomerular size, damage and sclerosis were reduced in AT2R-Tg after 12 weeks of 5/6 nephrectomy, whereas urinary NOx (nitrates and nitrites) were elevated as compared to the WT animals [88] . All the above-mentioned beneficial effects of AT2R overexpression were abolished by a concomitant inhibition of the AT2R with PD123319. Thus, the AT2R may serve as a potential therapeutic target for glomerular disorders.
In another type of chronic kidney disease, diabetic nephropathy (DN), the AT2R may also play a protective role. Type 1 diabetes was induced with low-dose streptozotocin in AT2R-KO and WT mice [89] . After 4 weeks, the AT2R-KO animals developed features of early DN including renal hypertrophy, tubular apoptosis, and progressive extracellular matrix (ECM) protein accumulation as well as increased GFR. Renal oxidative stress (as measured by heme oxygenase 1 and p47phox expression) was significantly elevated in AT2R-KO animals as compared to WT animals.
Recently a study that tested an impact of AT2R on obesityrelated kidney injury was published. After 16 weeks of high fat diet (HFD), the WT animals developed microalbuminuria, mesanglial matrix expansion and glomerular hypertrophy which were further increased in AT 2 KO mice [90] . Interestingly cortical expression of the AT1R and ACE and renal Ang II increased in AT2R-KO animals whereas cortical expression of MasR, ACE2 activity and renal Ang-(1-7) levels decreased compared to WT animals. This finding suggests that AT2R deficiency shifts the RAS from the protective towards harmful activity in obesity-related kidney injury.
AT2R stimulation in kidney diseases
Research on AT2R knock out or transgenic animals provides only indirect evidence on the potentially beneficial actions of AT2R stimulation in kidney diseases since these strategies cannot answer the question whether the observed effects are mediated by disrupted AT2R signalling or by altered nephrogenesis during prenatal development. Only pharmacological strategies targeting the angiotensin receptors (e.g. combination of ARBs with Ang II or AT2R blockers, and selective AT2R agonists) can provide direct evidence of AT2R-mediated renoprotection.
Obese Zucker rats is an animal model of metabolic syndrome, characterised by elevated levels of pro-inflammatory markers such as plasma CRP and MCP-1 and increased cortical TNF␣ expression as well as elevated oxidative stress (measured by increased plasma heme oxygenase HO-1 and reduced plasma SOD activity) as compared to lean rats. Two weeks of treatment with the AT2R agonist, CGP-42112A, led to a reduction of pro-inflammatory and oxidative stress markers in plasma and cortical tissue [91] . Since inflammation and oxidative stress are well-known contributors to kidney disease pathology, reduction of these markers may have a beneficial impact on disease progression (Fig. 2) . Interestingly, chronic treatment of obese Zucker rats with CGP-42112A led to increased cortical expression of ACE2, Ang-(1-7) and its Mas receptor while the AT1R, renin and ACE expression remained unaffected [92] (Fig. 2) . This is in contrast to the above-mentioned study where in high fat diet treated animals the AT2R deletion increased the components of "harmful" RAS suggesting that results obtained from studies with knock-out animals cannot be directly related to pharmacological manipulation of the protective arm of the RAS.
The impact of selective AT2R stimulation with C21 on diabetic nepropathy was studied in Zucker diabetic fatty rats [93] and in streptozotocin-injected ApoE −/− mice [94] . In Zucker fatty rats, C21 significantly reduced plasma uric acid and triglyceride levels as compared to the vehicle-or losartan-treated animals [93] . In both studies, treatment with C21 reduced albuminuria, fibrosis and renal inflammation indicating a therapeutical potential of AT2R stimulation in DN (Fig. 2) .
SHR-SP is a commonly used model in the cardiovascular research, characterised by hypertension-related cardiac, vascular and renal damage. Addition of high-salt diet (HSD) accelerates the pathological processes. In HSD-fed SHR-SP, treatment with C21 reduced proteinuria, vascular lesions, tubular damage, glomerular sclerosis and immune cell infiltration [95] . Interestingly, while AT2R stimulation massively reduced plasma renin activity, it had no impact on elevated BP during the HSD challenge (for vehicle and C21 BP increased from 160 ± 15 at baseline to 245 ± 15 after 6 weeks of HSD) indicating that the renoprotective effects of AT2R stimulation in hypertensive kidney disease were BP-independent.
Another commonly used animal model of CKD is doxorubicininduced nephropathy (DIN). Treatment with C21 of DIN rats prevented the reduction in glomerular density and size, accompanied by reduced oxidative stress in kidney tissue [96] . Interestingly, there were no significant differences between C21, captopril and olmesartan treatment representing standard of care in CKD.
Effects of AT2R stimulation were also evaluated in cyclosporine nephropathy, which is characterized mainly by tubulo-interstitial fibrosis. Treatment with C21 for 4 weeks significantly reduced glomerular and tubulo-interstitial fibrosis, type 1 collagen expression and macrophage infiltration as compared with rats treated only with cyclosporine [97] . Interestingly, the anti-fibrotic and antiinflammatory effects of C21 were also observed in myocardium. Thus, AT2R stimulation may represent a novel strategy for the treatment of type 4 cardio-renal syndrome (alteration of cardiac function in CKD [98] ).
All the studies discussed confirmed previously postulated protective effects of a selective AT2R stimulation in various kidney diseases including diabetic and hypertensive nephropathies, kidney fibrosis of various origins and cardio-renal syndrome ( Figs. 1 and 2 ).
Conclusions and Outlook
Since 1999, when the AT2R has been described as an enigmatic receptor with respect to signalling pathways and function [48] , our knowledge about AT2R expanded significantly. In the last years, molecular pathways underlying the protective action of the AT2R in tissue injuries [20] , the AT2R promoter regulation and its adapter proteins [56] as well as dimerization partners [99] have been described. Despite difficulties to assess its physiological role in healthy tissue or during fetal development, the AT2R-mediated beneficial actions became obvious in cardiovascular and renal diseases. Upregulated in disease (e.g. via Ang II, pro-inflammatory cytokines, oxidative stress or apoptosis) the AT2R counterbalance the pathological processes and limits spatiotemporal development of tissue injury. Thus, the AT2R may be classified as an integrative part of the natural protective system, defined here as a complex mechanism induced by various diseases counterbalancing pathological processes by targeting multiple pathways on the cellular, tissue, organ and endocrine levels (Box 1). Pharmacological activation of the protective system is a novel and attractive strategy that, instead of blocking a single detrimental pathway (e.g. inhibitors of pro-inflammatory cytokines and cytokine receptors), promotes Box 1: AT2R as a natural protective system. Natural protective system is a complex mechanism induced in various diseases counterbalancing pathological processes by targeting multiple pathways on the cellular, tissue, organ and endocrine levels that limits the spatiotemporal development of the injury. Based on scientific evidence, the AT2R along with the Ang-(1-7) receptor Mas, are integrative components of the natural protective system often defined asprotective armöf the RAS. Pharmacological activation of the protective system is a novel strategy for the treatment of complex multifactorial diseases (such as cardiovascular and renal diseases) that, instead of blocking a single detrimental pathway, promotes endogenous protective and regenerative processes.
endogenous protective and regenerative processes. Recently, two selective AT2R agonists (Compound 21 by Vicore Pharma, Sweden and MOR107 by Lanthio Pharma, Netherlands) have been developed and tested in Phase I trials demonstrating their safety in human subjects. Based on animal disease models, the selective AT2R stimulation provides beneficial effects in cardiovascular and renal diseases that need to be further tested in humans in efficacy Phase II/III trials.
